Merck announces EC approves SC administration of Keytruda for all adult indications approved in the European Union: Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...
Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.
As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...
Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in ...
Investor's Business Daily on MSN
Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.
Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more ...
Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...
Jazz Pharmaceuticals and Zymeworks announced positive topline phase 3 results for Ziihera in HER2-positive GEA. Click here to ...
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...
Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...
Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback